{"id":207932,"date":"2025-06-23T15:01:12","date_gmt":"2025-06-23T15:01:12","guid":{"rendered":"https:\/\/www.europesays.com\/uk\/207932\/"},"modified":"2025-06-23T15:01:12","modified_gmt":"2025-06-23T15:01:12","slug":"novo-nordisk-terminates-collaboration-with-hims-hers-health-inc-due-to-concerns-about-their-illegal-mass-compounding-and-deceptive-marketing","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/uk\/207932\/","title":{"rendered":"Novo Nordisk terminates collaboration with Hims &#038; Hers Health, Inc. due to concerns about their illegal mass compounding and deceptive marketing"},"content":{"rendered":"<ul type=\"disc\">\n<li><b>Collaboration of over one month has ended based on\u00a0Hims &amp; Hers deceptive promotion and selling of illegitimate, knockoff versions of Wegovy<\/b><b>\u00ae that put patient safety at risk<\/b><\/li>\n<li><b>Novo\u00a0Nordisk won&#8217;t stop taking action <\/b><b>to protect Americans from the dangers of illicit foreign active pharmaceutical ingredients in knock-off drugs<\/b><\/li>\n<li><b>Efforts will continue to make authentic, FDA-approved\u00a0Wegovy\u00ae directly available through NovoCare<\/b><b>\u00ae Pharmacy to select telehealth organizations that share our commitment to safe and effective medical treatment for patients living with chronic diseases <\/b><\/li>\n<\/ul>\n<p>PLAINSBORO, N.J., June 23, 2025 \/PRNewswire\/ &#8212; Novo Nordisk announced today that the company will no longer be working with Hims &amp; Hers Health, Inc., and that direct access to Wegovy\u00ae will no longer be available to Hims &amp; Hers Health, Inc. via NovoCare\u00ae\u00a0Pharmacy.<\/p>\n<p>In late April, the FDA resolved the Wegovy\u00ae\u00a0shortage based on its conclusion that Novo Nordisk is fully meeting current and projected nationwide demand for this medicine. In support of transitioning patients from knock-off compounded versions to authentic, FDA-approved Wegovy\u00ae through NovoCare\u00ae Pharmacy, Novo Nordisk began collaborating with telehealth companies. Over one month into the collaboration, Hims &amp; Hers Health, Inc. has failed to adhere to the law which prohibits mass sales of compounded drugs under the false guise of &#8220;personalization&#8221; and are disseminating deceptive marketing that put patient safety at risk.<\/p>\n<p>&#8220;Novo Nordisk is firm on our position and protecting patients living with obesity. When patients are prescribed semaglutide treatments by their licensed healthcare professional or a telehealth provider, they are entitled to receive authentic, FDA-approved and regulated Wegovy\u00ae,&#8221; said Dave Moore, Executive Vice President, US Operations of Novo Nordisk Inc. &#8220;We will work with telehealth companies to provide direct access to Wegovy\u00ae that share our commitment to patient safety \u2013 and when companies engage in illegal sham compounding that jeopardizes the health of Americans, we will continue to take action.&#8221;<\/p>\n<p>Novo Nordisk is deeply concerned and is continuing to take proactive measures to keep US patients safe from knock-off drugs made with foreign illicit active pharmaceutical ingredients. Based on Novo Nordisk&#8217;s investigation, the &#8220;semaglutide&#8221; active pharmaceutical ingredients that are in the knock-off drugs sold by telehealth entities and compounding pharmacies are manufactured by foreign suppliers in China. According to a report from the <a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=4454316-1&amp;h=538309300&amp;u=https%3A%2F%2Fwww.brookings.edu%2Farticles%2Fthe-wild-east-of-semaglutide%2F&amp;a=Brookings+Institute\" rel=\"nofollow noopener\" target=\"_blank\">Brookings Institute<\/a>,\u00a0FDA has never authorized or approved the manufacturing processes used by any of these foreign suppliers to make semaglutide, nor has FDA ever reviewed or authorized the quality of the &#8220;semaglutide&#8221; they produce. The report also found that a &#8220;large share of [these Chinese suppliers] were never inspected by FDA, and many of those that were [inspected] had drug quality assurance violations.&#8221; US patients should not be exposed to knock-off drugs made with unsafe and illicit foreign ingredients.<\/p>\n<p>More information can be found on <a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=4454316-1&amp;h=3504287780&amp;u=https%3A%2F%2Fwww.novomedlink.com%2Fsemaglutide%2Fpatient-safety.html%3Futm_medium%3Dvanity%26utm_source%3Dsemaglutidedotcom-redirect%26utm_campaign%3Dvanity-redirect%26utm_content%3Dsemaglutidedotcom-redirect&amp;a=semaglutide.com\" rel=\"nofollow noopener\" target=\"_blank\">semaglutide.com<\/a>.\u00a0\u00a0<\/p>\n<p><b>About obesity <\/b><\/p>\n<p>Obesity is a serious chronic, progressive, and complex disease that requires long-term management.1-3 One key misunderstanding is that this is a disease of just lack of willpower, when in fact there is underlying biology that may impede people with obesity from losing weight and keeping it off.2,3 Obesity is influenced by a variety of factors, including genetics, social determinants of health, and the environment.4,5<\/p>\n<p>The prevalence of overweight and obesity is a public health issue that has severe cost implications to healthcare systems.6,7 In the US, about 40% of adults live with obesity.8<\/p>\n<p><b>About NovoCare<\/b><b>\u00ae<\/b><b>\u00a0Pharmacy<\/b>\u00a0\u00a0<\/p>\n<p>NovoCare\u00ae Pharmacy provides cash-paying patients who have been prescribed Wegovy\u00ae with the ability to schedule shipments of their Wegovy\u00ae prescriptions directly to their home. Beyond convenient home delivery, NovoCare\u00ae also supports patients with benefit verification, refill reminders, and access to live support from a NovoCare\u00ae case manager. More information about NovoCare\u00ae Pharmacy is available at <a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=4454316-1&amp;h=3557773251&amp;u=https%3A%2F%2Fwww.novocare.com%2Fobesity%2Fproducts%2Fwegovy%2Fget-product.html&amp;a=NovoCare%C2%AE+pharmacy+%7C+NovoCare%C2%AE\" rel=\"nofollow noopener\" target=\"_blank\">NovoCare\u00ae pharmacy | NovoCare\u00ae<\/a>.<\/p>\n<p><b>About Wegovy<\/b><b>\u00ae<\/b><b>\u202f(semaglutide) injection 2.4 mg\u202f<\/b>\u00a0<\/p>\n<p><b>What is Wegovy<\/b><b>\u00ae<\/b><b>?\u00a0<\/b>\u00a0<\/p>\n<p>WEGOVY\u00ae\u00a0(semaglutide) injection 2.4 mg is an injectable prescription medicine used with a reduced calorie diet and increased physical activity:\u00a0\u00a0<\/p>\n<ul type=\"disc\">\n<li>to reduce the risk of major cardiovascular events such as death, heart attack, or stroke in adults with known heart disease and with either obesity or overweight.\u00a0<\/li>\n<li>that may help adults and children aged 12 years and older with obesity, or some adults with overweight who also have weight-related medical problems, to help them lose excess body weight and keep the weight off.\u00a0\u00a0<\/li>\n<\/ul>\n<p>Wegovy\u00ae\u00a0contains semaglutide and should not be used with other semaglutide-containing products or other GLP-1 receptor agonist medicines.\u00a0\u00a0<\/p>\n<p>It is not known if Wegovy\u00ae\u00a0is safe and effective for use in children under 12 years of age.\u00a0\u00a0<\/p>\n<p><b>Important Safety Information\u00a0<\/b>\u00a0<\/p>\n<p><b>What is the most important information I should know about Wegovy<\/b><b>\u00ae<\/b><b>? Wegovy<\/b><b>\u00ae <\/b><b>may cause serious side effects, including:\u00a0<\/b>\u00a0<\/p>\n<ul type=\"disc\">\n<li><b>Possible thyroid tumors, including cancer.<\/b>\u00a0Tell your healthcare provider if you get a lump or swelling in your neck, hoarseness, trouble swallowing, or shortness of breath. These may be symptoms of thyroid cancer. In studies with rodents, Wegovy\u00ae and medicines that work like Wegovy\u00ae\u00a0caused thyroid tumors, including thyroid cancer. It is not known if Wegovy\u00ae\u00a0will cause thyroid tumors or a type of thyroid cancer called medullary thyroid carcinoma (MTC) in people\u00a0\u00a0<\/li>\n<li>Do not use\u00a0Wegovy\u00ae\u00a0if you or any of your family have ever had a type of thyroid cancer called medullary thyroid carcinoma (MTC) or if you have an endocrine system condition called Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)\u00a0\u00a0<\/li>\n<\/ul>\n<p><b>Do not use Wegovy<\/b><b>\u00ae<\/b><b>\u00a0if:\u00a0<\/b>\u00a0<\/p>\n<ul type=\"disc\">\n<li>you or any of your family have ever had a type of thyroid cancer called\u00a0medullary thyroid carcinoma (MTC) or if you have an endocrine system condition called Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)\u00a0<\/li>\n<li>you have had a serious allergic reaction to\u00a0semaglutide or any of the ingredients in Wegovy\u00ae\u00a0<\/li>\n<\/ul>\n<p><b>Before using Wegovy<\/b><b>\u00ae<\/b><b>, tell your healthcare provider if you have any other medical conditions, including if you:\u00a0<\/b>\u00a0<\/p>\n<ul type=\"disc\">\n<li>have or have had problems with your pancreas or kidneys\u00a0<\/li>\n<li>have type 2 diabetes and a history of diabetic retinopathy\u00a0<\/li>\n<li>have or have had depression, suicidal thoughts, or mental health issues\u00a0\u00a0<\/li>\n<li>are scheduled to have surgery or other procedures that use anesthesia or deep sleepiness (deep sedation)\u00a0<\/li>\n<li>are pregnant or plan to become pregnant.\u00a0Wegovy\u00ae may harm your unborn baby. You should stop using Wegovy\u00ae 2 months before you plan to become pregnant\u00a0<\/li>\n<li>are\u00a0breastfeeding or plan to breastfeed. It is not known if Wegovy\u00ae passes into your breast milk\u00a0\u00a0<\/li>\n<\/ul>\n<p><b>Tell your healthcare provider about all the medicines you take,<\/b>\u00a0including prescription and over-the-counter medicines, vitamins, and herbal supplements. Wegovy\u00ae\u00a0may affect the way some medicines work and some medicines may affect the way Wegovy\u00ae\u00a0works. Tell your healthcare provider if you are taking other medicines to treat diabetes, including sulfonylureas or insulin. Wegovy\u00ae slows stomach emptying and can affect medicines that need to pass through the stomach quickly.\u00a0\u00a0<\/p>\n<p><b>What are the possible side effects of Wegovy<\/b><b>\u00ae<\/b><b>?\u00a0<\/b>\u00a0<\/p>\n<p><b>Wegovy<\/b><b>\u00ae<\/b><b>\u00a0may cause serious side effects, including:<\/b>\u00a0<\/p>\n<ul type=\"disc\">\n<li><b>inflammation of your pancreas (pancreatitis).<\/b>\u00a0Stop using Wegovy\u00ae\u00a0and call your healthcare provider right away if you have severe pain in your stomach area (abdomen) that will not go away, with or without vomiting. You may feel the pain from your abdomen to your back\u00a0\u00a0<\/li>\n<li><b>gallbladder problems.<\/b> Wegovy\u00ae\u00a0may cause gallbladder problems, including gallstones. Some gallstones may need surgery. Call your healthcare provider if you have symptoms, such as pain in your upper stomach (abdomen), fever, yellowing of the skin or eyes (jaundice), or clay-colored stools\u00a0<\/li>\n<li><b>increased risk of low blood sugar (hypoglycemia), especially those who also take medicines for diabetes such as insulin or\u00a0sulfonylureas.<\/b>\u00a0This can be a serious side effect. Talk to your healthcare provider about how to recognize and treat low blood sugar and check your blood sugar before you start and while you take Wegovy\u00ae. Signs and symptoms of low blood sugar may include dizziness or light-headedness, blurred vision, anxiety, irritability or mood changes, sweating, slurred speech, hunger, confusion or drowsiness, shakiness, weakness, headache, fast heartbeat, or feeling jittery\u00a0<\/li>\n<li><b>kidney problems (kidney failure).<\/b>\u00a0In people who have kidney problems, diarrhea, nausea, and vomiting may cause a loss of fluids (dehydration), which may cause kidney problems to get worse. It is important for you to drink fluids to help reduce your chance of dehydration\u00a0<\/li>\n<li><b>severe stomach problems.<\/b>\u00a0Stomach problems, sometimes severe, have been reported in people who use Wegovy\u00ae. Tell your healthcare provider if you have stomach problems that are severe or will not go away.\u00a0<\/li>\n<li><b>serious allergic reactions.<\/b>\u00a0Stop using Wegovy\u00ae\u00a0and get medical help right away, if you have any symptoms of a serious allergic reaction, including swelling of your face, lips, tongue, or throat; problems breathing or swallowing; severe rash or itching; fainting or feeling dizzy; or very rapid heartbeat\u00a0\u00a0<\/li>\n<li><b>change in vision in people with type 2 diabetes.<\/b>\u00a0Tell your healthcare provider if you have changes in vision during treatment with Wegovy\u00ae\u00a0\u00a0<\/li>\n<li><b>increased heart rate.<\/b> Wegovy\u00ae\u00a0can increase your heart rate while you are at rest. Tell your healthcare provider if you feel your heart racing or pounding in your chest and it lasts for several minutes\u00a0<\/li>\n<li><b>depression or thoughts of suicide.<\/b>\u00a0You should pay attention to any mental changes, especially sudden changes in your mood, behaviors, thoughts, or feelings. Call your healthcare provider right away if you have any mental changes that are new, worse, or worry you\u00a0<\/li>\n<li><b>food or liquid getting into the lungs during surgery or other procedures that use anesthesia or deep sleepiness (deep sedation).<\/b>\u00a0Wegovy\u00ae\u00a0may increase the chance of food getting into your lungs during surgery or other procedures. Tell all your healthcare providers that you are taking Wegovy\u00ae\u00a0before you are scheduled to have surgery or other procedures\u00a0\u00a0<\/li>\n<\/ul>\n<p><b>The most common side effects of Wegovy<\/b><b>\u00ae<\/b><b> may include:<\/b>\u00a0nausea, diarrhea, vomiting, constipation, stomach (abdomen) pain, headache, tiredness (fatigue), upset stomach, dizziness, feeling bloated, belching, low blood sugar in people with type 2 diabetes, gas, stomach flu, heartburn, and runny nose or sore throat.\u00a0<\/p>\n<p><b>Please see Medication Guide and Prescribing Information, including Boxed Warning, for Wegovy<\/b><b>\u00ae<\/b><b>\u00a0at <\/b><a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=4454316-1&amp;h=1849362782&amp;u=https%3A%2F%2Fwww.novo-pi.com%2Fwegovy.pdf&amp;a=https%3A%2F%2Fwww.novo-pi.com%2Fwegovy.pdf\" rel=\"nofollow noopener\" target=\"_blank\">https:\/\/www.novo-pi.com\/wegovy.pdf<\/a>\u00a0<\/p>\n<p><b>About Novo Nordisk<\/b><\/p>\n<p>Novo Nordisk is a leading global healthcare company that&#8217;s been making innovative medicines to help people with diabetes lead longer, healthier lives for more than 100 years. This heritage has given us experience and capabilities that also enable us to drive change to help people defeat other serious chronic diseases such as obesity, rare blood, and endocrine disorders. We remain steadfast in our conviction that the formula for lasting success is to stay focused, think long-term, and do business in a financially, socially, and environmentally responsible way. With a US presence spanning 40 years, Novo Nordisk US is headquartered in\u00a0New Jersey and employs over 10,000 people throughout the country across 12 manufacturing, R&amp;D and corporate locations in eight states plus\u00a0Washington DC. For more information, visit\u00a0<a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=4454316-1&amp;h=2328769457&amp;u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D4365868-1%26h%3D3558636689%26u%3Dhttps%253A%252F%252Fc212.net%252Fc%252Flink%252F%253Ft%253D0%2526l%253Den%2526o%253D4349237-1%2526h%253D2350167128%2526u%253Dhttps%25253A%25252F%25252Fc212.net%25252Fc%25252Flink%25252F%25253Ft%25253D0%252526l%25253Den%252526o%25253D4248685-1%252526h%25253D1648513612%252526u%25253Dhttps%2525253A%2525252F%2525252Fc212.net%2525252Fc%2525252Flink%2525252F%2525253Ft%2525253D0%25252526l%2525253Den%25252526o%2525253D4243585-1%25252526h%2525253D3380893495%25252526u%2525253Dhttps%252525253A%252525252F%252525252Fc212.net%252525252Fc%252525252Flink%252525252F%252525253Ft%252525253D0%2525252526l%252525253Den%2525252526o%252525253D4109213-1%2525252526h%252525253D808952762%2525252526u%252525253Dhttps%25252525253A%25252525252F%25252525252Fwww.novonordisk-us.com%25252525252F%2525252526a%252525253Dnovonordisk-us.com%25252526a%2525253Dnovonordisk-us.com%252526a%25253Dnovonordiskus.com%2526a%253Dnovonordisk-us.com%26a%3Dnovonordisk-us.com&amp;a=novonordisk-us.com\" rel=\"nofollow noopener\" target=\"_blank\">novonordisk-us.com<\/a>,\u00a0<a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=4454316-1&amp;h=1113145732&amp;u=https%3A%2F%2Fwww.facebook.com%2FNovoNordiskUS%2F&amp;a=Facebook\" rel=\"nofollow noopener\" target=\"_blank\">Facebook<\/a>,\u00a0<a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=4454316-1&amp;h=2822795931&amp;u=https%3A%2F%2Fwww.instagram.com%2Faccounts%2Flogin%2F%3Fnext%3Dhttps%253A%252F%252Fwww.instagram.com%252Fnovonordiskus%252F%26is_from_rle&amp;a=Instagram\" rel=\"nofollow noopener\" target=\"_blank\">Instagram<\/a>, and\u00a0<a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=4454316-1&amp;h=3759777712&amp;u=https%3A%2F%2Fx.com%2Fnovonordiskus&amp;a=X\" rel=\"nofollow noopener\" target=\"_blank\">X<\/a>.<\/p>\n<p>Novo Nordisk is committed to the responsible use of our semaglutide-containing medicines which represent distinct products with different indications, dosages, prescribing information, titration schedules, and delivery forms. These products are not interchangeable and should not be used outside of their approved indications. Learn more at <a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=4454316-1&amp;h=3504287780&amp;u=https%3A%2F%2Fwww.novomedlink.com%2Fsemaglutide%2Fpatient-safety.html%3Futm_medium%3Dvanity%26utm_source%3Dsemaglutidedotcom-redirect%26utm_campaign%3Dvanity-redirect%26utm_content%3Dsemaglutidedotcom-redirect&amp;a=semaglutide.com\" rel=\"nofollow noopener\" target=\"_blank\">semaglutide.com<\/a>.<\/p>\n<p><b>Contacts for further information<\/b><\/p>\n<p><b>References:<\/b><\/p>\n<p>1.\u00a0 Kaplan LM, Golden A,\u00a0Jinnett K, et al. Perceptions of barriers to effective obesity care: results from the national action study.\u00a0Obesity. 2018;26(1):61-69.\u00a0<\/p>\n<p>2.\u00a0 Bray GA, Kim\u00a0KK, Wilding JPH; World Obesity Federation. Obesity: a chronic relapsing progressive disease process. A position statement of the World Obesity Federation.\u00a0Rev. 2017;18(7):715-723.\u00a0<\/p>\n<p>3.\u00a0 Garvey WT, Mechanick JI, Brett EM, et al. American association of clinical endocrinologists and American College\u00a0of Endocrinology comprehensive clinical practice guidelines for medical care of patients with obesity.\u00a0Endocr Pract. 2016;22 (Suppl 3):1-203.<\/p>\n<p>4.\u00a0 Centers for Disease Control and Prevention. Adult obesity facts. Last accessed:\u00a0June 2025. Available at:\u00a0<a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=4454316-1&amp;h=2627195168&amp;u=https%3A%2F%2Fwww.cdc.gov%2Fobesity%2Fadult-obesity-facts%2Findex.html&amp;a=https%3A%2F%2Fwww.cdc.gov%2Fobesity%2Fadult-obesity-facts%2Findex.html\" rel=\"nofollow noopener\" target=\"_blank\">https:\/\/www.cdc.gov\/obesity\/adult-obesity-facts\/index.html<\/a>.<\/p>\n<p>5.\u00a0 World Obesity Federation. World Obesity Atlas 2023. Last accessed:\u00a0June 2025. Available at:\u00a0<a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=4454316-1&amp;h=1688981294&amp;u=https%3A%2F%2Fwww.worldobesity.org%2Fresources%2Fresource-library%2Fworld-obesity-atlas-2023&amp;a=https%3A%2F%2Fwww.worldobesity.org%2Fresources%2Fresource-library%2Fworld-obesity-atlas-2023\" rel=\"nofollow noopener\" target=\"_blank\">https:\/\/www.worldobesity.org\/resources\/resource-library\/world-obesity-atlas-2023<\/a>.<\/p>\n<p>6.\u00a0 Centers for Disease Control and Prevention. Risk Factors for Obesity. Last accessed:\u00a0June 2025. Available at:\u00a0<a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=4454316-1&amp;h=4262615422&amp;u=https%3A%2F%2Fwww.cdc.gov%2Fobesity%2Frisk-factors%2Frisk-factors.html&amp;a=https%3A%2F%2Fwww.cdc.gov%2Fobesity%2Frisk-factors%2Frisk-factors.html\" rel=\"nofollow noopener\" target=\"_blank\">https:\/\/www.cdc.gov\/obesity\/risk-factors\/risk-factors.html<\/a>.<\/p>\n<p>7.\u00a0 Centers for Disease Control and Prevention. Why it matters. Last accessed:\u00a0June 2025. Available at:\u00a0<a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=4454316-1&amp;h=2142725477&amp;u=https%3A%2F%2Fwww.cdc.gov%2Fobesity%2Fphp%2Fabout%2F%3FCDC_AAref_Val%3Dhttps%3A%2F%2Fwww.cdc.gov%2Fobesity%2Fabout-obesity%2Fwhy-it-matters.html&amp;a=https%3A%2F%2Fwww.cdc.gov%2Fobesity%2Fphp%2Fabout%2F%3FCDC_AAref_Val%3Dhttps%3A%2F%2Fwww.cdc.gov%2Fobesity%2Fabout-obesity%2Fwhy-it-matters.html\" rel=\"nofollow noopener\" target=\"_blank\">https:\/\/www.cdc.gov\/obesity\/php\/about\/?CDC_AAref_Val=https:\/\/www.cdc.gov\/obesity\/about-obesity\/why-it-matters.html<\/a>.\u00a0<\/p>\n<p>8.\u00a0 Centers for Disease Control and Prevention. Obesity and Severe Obesity Prevalence in Adults:\u00a0United States, August 2021\u2013August 2023. Last accessed\u00a0June 2025. Available at:\u00a0<a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=4454316-1&amp;h=3405121502&amp;u=https%3A%2F%2Fwww.cdc.gov%2Fnchs%2Fproducts%2Fdatabriefs%2Fdb508.htm&amp;a=https%3A%2F%2Fwww.cdc.gov%2Fnchs%2Fproducts%2Fdatabriefs%2Fdb508.htm\" rel=\"nofollow noopener\" target=\"_blank\">https:\/\/www.cdc.gov\/nchs\/products\/databriefs\/db508.htm<\/a><\/p>\n<p>SOURCE NOVO NORDISK INC.<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/rt.prnewswire.com\/rt.gif?NewsItemId=NY15727&amp;Transmission_Id=202506230803PR_NEWS_USPR_____NY15727&amp;DateId=20250623\" style=\"border:0px; width:1px; height:1px;\"\/><\/p>\n<p>        <script async src=\"\/\/www.instagram.com\/embed.js\"><\/script><\/p>\n","protected":false},"excerpt":{"rendered":"Collaboration of over one month has ended based on\u00a0Hims &amp; Hers deceptive promotion and selling of illegitimate, knockoff&hellip;\n","protected":false},"author":2,"featured_media":67138,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4316],"tags":[105,4348,34013,16,15],"class_list":{"0":"post-207932","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-healthcare","8":"tag-health","9":"tag-healthcare","10":"tag-novo-nordisk-inc","11":"tag-uk","12":"tag-united-kingdom"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@uk\/114733284355000942","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/posts\/207932","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/comments?post=207932"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/posts\/207932\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/media\/67138"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/media?parent=207932"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/categories?post=207932"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/tags?post=207932"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}